tbuckley/cabot-search huggingface dataset:
Cisplatin (C)-paclitaxel (P) chemotherapy (CT) regimen with concurrent radiotherapy (RT) in local advanced (LACC) or recurrent (LRCC) cervical cancer: 14 year-results of a phase II study.
Authors: Milena Bruzzone, Chiara Dellepiane, Elisa Bo, Alessia Cavo, Flavio Giannelli, Maria Grazia Centurioni, Maurizio Cosso, Franco Alessandri, Valerio Gaetano Vellone, Rodolfo Sirito, Elisa Zanardi, Giulia Buzzatti, Carlo Messina, Carlo Cattrini, Claudio Gustavino, Francesco Boccardo
Journal: Journal of Clinical Oncology (2016)

5529 Background: concurrent CT-RT is the standard treatment for LACC. Currently weekly low dose Cisplatin based CT is the radio-sensitizing treatment suggested. Our single-center, prospective, single-arm, phase II study evaluates activity and toxicity of C-P regimen administered every 3 weeks for 4 courses, at cytotoxic dose, with concurrent RT in LACC or LRCC patients (pts). Methods: Inclusion criteria: LACC (FIGO stage IB2–IVB) or LRCC after hysterectomy, ECOG 0-1, Age 18-75. Cisplatin (75 mg/m2) and Paclitaxel (175 mg/m2) every 21 days, for 4 courses were administered with concurrent RT (50 Gy, 25 courses) and high-dose rate brachytherapy (6 Gy, 3 courses). Pelvic RT started 2 weeks after CT cycle 1, 1st brachytherapy insertion was carried out during CT cycle 4. Overall Survival (OS) and Progression Free Survival (PFS) were evaluated by Kaplan-Meier method, Response by RECIST 1.1, toxicity by NCI CTC. Simon's optimal two stage design was applied: P0 = 20% (complete response (CR) < 20% was of no interest), P1 = 40%; for a power of 80% 13 pts had to be enrolled into the 1st stage (α = 0.05, ß = 0.20). Results: Between 2000 and 2014, 65 pts were enrolled: 57 LACC and 8 LRCC after hysterectomy. 2 pts died during the treatment, due to causes not tumor/therapy related: one of these pts was not evaluable for response but everyone was considered for toxicity and survival analysis. Among 64 pts evaluable for response: 55 CR (84.62%), 8 Partial Response (PR) (12.31%), 1 Stable Disease (1.54%) were observed, Response Rate (RR = CR+PR) 96.92% (95% CI: 92.71%-100%). Median follow up: 58 months (2-184), PFS and OS are 66.6% and 67.3% respectively at 180 months from the study start. 2 pts died during the follow up due to second primary cancers. A grade (G) 4 toxicity was reported (leukopenia), G3 toxicities detected were: proctitis (24.61%), leukopenia (15.38%), anemia (15.38%), diarrhea (13.85%), emesis (6.15%), cystitis (6.15%), thrombocytopenia (1.54%). Conclusions: At a long term follow up Cisplatin-Paclitaxel regimen with concurrent RT shows an important activity and a good safety profile in LACC or LRCC patient.
Christmas Gifts Fund
Authors: Z. Cope
Journal: BMJ (1961)

Sir,?I should be grateful if you would allow me space to make the customary annual appeal to enable the Royal Medical Benevolent Fund to send a special Christmas gift to each of its regular beneficiaries. Last year to our delight but not surprise there was a very generous response which brought gladness to the hearts of many. In making this appeal for Christmas, 1962, we hope, nay we believe, that the members of our profession will respond as generously as or even more generously than last year. Would donors kindly send their contributions marked  Christmas Gifts  to the Royal Medical Benevolent Fund, 37 St. George's Road, Wimbledon, London S.W. 19 ??I am, etc., Zachary Cope, President, Royal Medical Benevolent Fund.
Abstract S6-03: Anastrozole versus tamoxifen for the prevention of loco-regional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ (IBIS-II DCIS)
Authors: J Cuzick, JF Forbes, I Sestak, A Howell, B Bonanni, N Bundred, C Levy, G von Minckwitz, W Eiermann, P Neven, M Stierer, C Holcombe, RE Coleman, LJ Jones, I Ellis
Journal: Cancer Research (2016)

Abstract Background: Third generation aromatase inhibitors are a more effective treatment option than tamoxifen for hormone receptor positive invasive breast cancer in postmenopausal women. However, it is not known whether anastrozole is more effective than tamoxifen in preventing the recurrence of breast cancer in women with hormone receptor (HR) positive ductal carcinoma in situ (DCIS). Here, we compare the efficacy of anastrozole versus tamoxifen in postmenopausal women with HR positive DCIS. Methods: A multi-centre randomised placebo-controlled trial of 1mg/day anastrozole (oral) vs. 20mg/day tamoxifen (oral) for five years was conducted in 2980 postmenopausal women with locally excised HR positive DCIS. The primary endpoint was to determine if anastrozole is at least as effective as tamoxifen in loco-regional control and prevention of contralateral disease. Secondary endpoints included breast cancer mortality, other cancers, cardiovascular disease, fractures, adverse events and non-breast cancer deaths. All analyses were done on an intention-to-treat basis and Cox proportional hazard were used to compute hazard ratios and corresponding confidence intervals for recurrence. Results: Between 2003 and 2012, a total of 2980 postmenopausal women were recruited into the IBIS-II DCIS trial. 1471 women were randomly assigned to receive anastrozole and 1509 women tamoxifen. Median follow-up for this first analysis is 6.8 years and 131 breast cancer recurrences have been recorded. Median age was 60.3 years (56.1-64.6), median BMI was 26.7 (23.6-30.7), and 45.6% of women had used hormone replacement therapy (HRT) before joining the trial. Of the 131 women with recurrent disease, 77 had a loco-regional recurrence and 51 reported contralateral disease. A total of 61 deaths were recorded. We will present a comprehensive analysis of the efficacy of anastrozole and tamoxifen for preventing loco-regional/contralateral breast cancer and major adverse events by intention to treat (ITT). Conclusions: To follow. Citation Format: Cuzick J, Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W, Neven P, Stierer M, Holcombe C, Coleman RE, Jones LJ, Ellis I. Anastrozole versus tamoxifen for the prevention of loco-regional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ (IBIS-II DCIS). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr S6-03.
THE CHALLENGE OF THE COMPUTER
Authors: W S WIGGINS
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Best Way to Quit Smoking: Cold Turkey
Authors: Anita Slomski
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Exploring new worlds: expanding the reach of qualitative research in dermatology
Authors: P. A. Nelson
Journal: British Journal of Dermatology (2016)

Qualitative researchers want to do things and go places that [dermatology] has not been able to reach before So never assume we lack ambition. The quote comes originally from psychology, where in recent years, research has been seen to 'open up new frontiers'1 by broadening the scope of methods to encompass more widespread use of qualitative approaches, unlocking new vistas and perspectives. The opening quote is playful, the point serious. We should be no less ambitious for dermatology in seeking to uncover the underlying processes shaping the beliefs and behaviour of patients with skin conditions and their clinicians. Qualitative methods can extend the understanding of these psychological and social factors, which impact directly on patient care – and are amenable to change. A recent open letter signed by 75 senior academics (with over 30 000 hits and rising) challenged The BMJ to develop an official policy on qualitative research and to establish explicit guidelines for judging qualitative submissions.2 The letter follows publication on Twitter of a rejection letter declaring qualitative studies to be 'low priority' for the journal because they are 'not as widely accessed, downloaded or cited' as other research.2 The authors refute the assertion, demonstrate that some of The BMJ's top papers are in point of fact qualitative, and challenge the journal to join the International Cochrane Collaboration and the Health Technology Assessment Programme in a position that quantitative vs. qualitative research is 'yesterday's war'. Here at the BJD there has already been explicit recognition that high‐quality qualitative research needs to be more visible in dermatology,3 with a call for well‐executed, well‐written qualitative studies in the journal and the recent launch of qualitative reporting standards as part of the new author guidelines.4
Zika Virus Infects Human Placental Macrophages
Authors: Kendra M. Quicke, James R. Bowen, Erica L. Johnson, Circe E. McDonald, Huailiang Ma, Justin T. O’Neal, Augustine Rajakumar, Jens Wrammert, Bassam H. Rimawi, Bali Pulendran, Raymond F. Schinazi, Rana Chakraborty, Mehul S. Suthar
Journal: Cell Host & Microbe (2016)
The Glycogen Content of Cell Suspensions Prepared from Massive Tissue Culture: Comparison of Cells Derived from Mouse Connective Tissue and Mouse Liver
Authors: Benton B. Westfall, Virginia J. Evans, John E. Shannon, Jr., Wilton R. Earle
Journal: JNCI Journal of the National Cancer Institute (1953)

Journal Article The Glycogen Content of Cell Suspensions Prepared from Massive Tissue Culture: Comparison of Cells Derived from Mouse Connective Tissue and Mouse Liver Get access Benton B. Westfall, Benton B. Westfall Endocrinology Service, Research Medicine Branch, and the Tissue Culture Section, Laboratory of Biology, National Cancer Institute,4Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar Virginia J. Evans, Virginia J. Evans Endocrinology Service, Research Medicine Branch, and the Tissue Culture Section, Laboratory of Biology, National Cancer Institute,4Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar John E. Shannon, Jr., John E. Shannon, Jr. Endocrinology Service, Research Medicine Branch, and the Tissue Culture Section, Laboratory of Biology, National Cancer Institute,4Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar Wilton R. Earle Wilton R. Earle Endocrinology Service, Research Medicine Branch, and the Tissue Culture Section, Laboratory of Biology, National Cancer Institute,4Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 14, Issue 3, December 1953, Pages 655–668, https://doi.org/10.1093/jnci/14.3.655 Published: 01 December 1953 Article history Received: 15 July 1953 Published: 01 December 1953
Abstract P1-08-07: Predisposing germline mutations in a clinic based breast cancer (BC) population
Authors: JE Garber, NM Tung, EP Elkin, BA Allen, NU Singh, R Wenstrup, A-R Hartman, EP Winer, NU Lin
Journal: Cancer Research (2016)

Abstract Background: Evaluation of women with BC for germline mutations associated with hereditary breast and ovarian cancer (HBOC) has become increasingly common due to its impact on management. Guidelines for genetic evaluation indicate testing for cases with early onset, triple negative disease or family cancer history. However, the majority of breast cancer occurs in patients without these high risk characteristics. The prevalence of mutations associated with HBOC has not been well characterized in this population. Methods: We performed a cross sectional study using DNA from blood samples from consecutive new invasive BC patients seen at the Dana-Farber Cancer Institute (01/01/2010 to 07/31/2102) who consented to research. Subjects were otherwise unselected. Mutations in 25 cancer genes were identified using a next generation sequencing based panel. Germline sequence variations and large rearrangements were classified for pathogenicity. Results: 456 samples from eligible subjects were included. The mean age of BC diagnosis was 50 years. Mutations were found in 51 women, 49 of which were associated with breast cancer (10.8%, 95% CI 8.1-14.0). BRCA1/2 mutations were found in 6.6% [95% CI 4.5-9.2%] while mutations in other BC-associated genes were found in 4.4% [95% CI 2.7-6.7%], particularly CHEK2 (2.2%, 95% CI 1.1, 4.0). Of the 49 women with BC-related mutations, 21 (43%) had BC diagnosed after age 45. In univariate analyses, age at diagnosis, Ashkenazi Jewish ancestry, triple negative histology and family BC/ovarian cancer (OC) history were associated with BRCA1/2 mutations, but no factors were significantly associated with mutations in other genes. Among 261 women with no FDR/SDR with BC/OC, 26 (10.0%) had a mutation. Nineteen mutations (10 BRCA1/2) were found in the 256 women (7.4%) who had not had previous genetic testing. Conclusions: In a single academic institution, 11% of new breast cancer patients had a germline mutation in a breast cancer predisposition gene: 6.6% were in BRCA1/2. The elevated prevalence compared to population-based series may reflect the practice composition of academic centers, which often attract women younger at BC diagnosis. In an academic practice with an active cancer genetics program, 10 women with BRCA1/2 and 9 with other mutations had not had genetic testing. Expanded testing identifies additional predisposing mutations, the utility of which are being defined for the care of breast cancer patients and their families. Citation Format: Garber JE, Tung NM, Elkin EP, Allen BA, Singh NU, Wenstrup R, Hartman A-R, Winer EP, Lin NU. Predisposing germline mutations in a clinic based breast cancer (BC) population. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-08-07.
Brain Metabolism and Cerebral Disorders
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
BENCE JONES PROTEIN IN THE URINE
Authors: R PHLIPPEN
Journal: JAMA (1960)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Inhibition of G9a Methyltransferase in Adult Human Erythroblasts Stimulates Fetal Hemoglobin Production By Facilitating Looping Between LCR and γ-Globin Gene
Authors: Ivan Krivega, Colleen Byrnes, Jaira F. de Vasconcellos, Y. Terry Lee, Megha Kaushal, Ann Dean, Jeffery L. Miller
Journal: Blood (2014)
Outbreak of tularaemia in brown hares (Lepus europaeus) in France, January to March 2011
Authors: A Decors, C Lesage, E Jourdain, P Giraud, P Houbron, P Vanhem, N Madani
Journal: Eurosurveillance (2011)

We report an outbreak of tularaemia in brown hares (Lepus europaeus) in France, which occurred from January to March 2011 and was characterised by a high mortality rate in the local hare population. In France, hare tularaemia is usually sporadic and does not significantly affect hare populations. The epizootic form of the outbreak reported here led us to reconsider the potential associated risks for hare populations and public health.
An Unusual Presentation of Chronic Myelogenous Leukemia: A Review of Isolated Central Nervous System Relapse
Authors: Scott M. Lindhorst, Richard D. Lopez, Ronald D. Sanders
Journal: Journal of the National Comprehensive Cancer Network (2013)

Many effective therapeutic options are available for patients with chronic myelogenous leukemia (CML). Imatinib, a first-generation tyrosine kinase inhibitor (TKI), is one of several options for patients who present with CML, whether in chronic phase, accelerated phase, or blast crisis. Although CML is very responsive to the selective TKIs, with response rates in chronic phase of greater than 90%, unusual presentations have been documented. Response rates for patients with CML in accelerated phase and blast crisis are notably lower to both first- and second-generation TKIs. This report presents a recent case of a young woman with newly diagnosed CML who presented with an accelerated phase isolated central nervous system (CNS) relapse after standard imatinib therapy, who initially experienced a complete hematologic response. Further treatment options, and monitoring of disease response, are discussed. Aggressive strategies, such as intrathecal chemotherapy, change in tyrosine kinase inhibitor to one with increased CNS penetration, and consideration of allogenic stem cell transplantation, are potential therapeutic modalities. Prophylaxis of the CNS in patients deemed at risk is an area requiring further study.
Abstract B13: In vitro animal cancer model for assessment of sulfated polysaccharides extract of Ulva lactuca as colon cancer therapeutic and chemopreventive agents
Authors: Marwa Abu-Serie, Maha El Demellawy, Mohamed El-Sayed, Fatma El-Rashidy
Journal: Cancer Research (2016)

Abstract Purpose: Sulfated polysaccharides extract of Ulva lactuca (ULSP) was in vitro assessed as probable chemopreventive and therapeutic agents for colon cancer (CC) comparing with currently used chemotherapy (5-fluorouracil “5-FU” and mitomycin-C “MMC”) using our newly developed in vitro transformed cancerous rat colon epithelial cells. Methods: The present study used an in vitro animal CC model as it resembles human multistage of chromosomal instability type of CC that is located mainly at distal colon. Hence, this model was used for evaluating ULSP by the detection of cytotoxicity against normal and cancerous colon cells and antimetastatic potency. Besides, ULSP efficacy as CC chemopreventive agent was assessed through the detection of CC progression markers; loss of heterozygosity of deleted in colorectal cancer (DCC) and p53, aldehyde dehydrogenase (ALDH) 1B1 expression, activities of ornithine decarboxylase (ODC), cyclooxygenase-2 (COX-2) and alkaline phosphatase (ALP), cellular redox state (Eh), doubling time, and mucin level. Results: The apoptosis-dependent anticancer activity of ULSP (4.9 µg/ml) was revealed at all stages of cancerous distal colon epithelial cells by the formation of apoptotic bodies and DNA fragmentation (above 43%) without affecting normal colon epithelial cells. Also, its inhibitory effect on the invasion of cancerous epithelial and Caco-2 cells (above 49%) was stronger than that of 5-FU+MMC (about 11%). Cells were treated with ULSP before exposure to CC inducers and they showed normal tumor suppressor genes (DCC and p53), normal expression of ALDH1B1, and normal activity of ODC (0.03±0.0004 U/μg) and null activity of COX-2. In addition, their normal pattern of proliferations (doubling time 3 days and Eh 252.7±2.12 mV) and differentiation was confirmed by the maintenance of ALP activity (0.46±0.01 mU/μg) and the secretion of mucin (29.2±0.2 μg/ml) compared to normal and cancerous colon epithelial cells. Conclusion: Our innovative in vitro model of colon cancer have proved that ULSP could have induced apoptosis at all stages of cancerous colon cells, inhibited cancerous cells to metastasize and blocked CC progression without effect on normal epithelial cells comparable to chemotherapy. Citation Format: Marwa Abu-Serie, Maha El Demellawy, Mohamed El-Sayed, Fatma El-Rashidy. In vitro animal cancer model for assessment of sulfated polysaccharides extract of Ulva lactuca as colon cancer therapeutic and chemopreventive agents. [abstract]. In: Proceedings of the Fourth AACR International Conference on Frontiers in Basic Cancer Research; 2015 Oct 23-26; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2016;76(3 Suppl):Abstract nr B13.